Report on 547 New Medicines in Development for Neurological Disorders Released in S...( SAN ANTONIO March 5 -- The Pharm...),Health
Navigation Links
Report on 547 New Medicines in Development for Neurological Disorders Released in San Antonio
Date:3/5/2008
SAN ANTONIO, March 5 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) delivered a new report today on medicines in the research pipeline for neurological diseases. The report found America's pharmaceutical research companies are testing 547 new medicines to help treat neurological diseases.
"We released this report in San Antonio because of its particular relevance to the health of this city's population and to the population in Texas," said PhRMA Senior Vice President Ken Johnson. The report was unveiled at the University Center for Community Health. "Over half of San Antonio's population is Hispanic, and Texas has the second largest Hispanic population in the country. Some of the diseases highlighted in the report, including epilepsy, stroke, Alzheimer's disease and lupus, are among the diseases that disproportionately affect Hispanic Americans."
According to the Epilepsy Foundation, for example, seizures are twice as common in Hispanics as they are in non-Hispanics and lupus is twice as prevalent among Hispanic women as it is among Caucasian women. The Alzheimer's Foundation has found that Hispanics are at greater risk to develop dementia than the rest of the population, and the number of Hispanics with Alzheimer's disease is expected to grow dramatically in the coming years. Additionally, stroke has been found to be the fourth leading cause of death among Hispanics, according to the American Stroke Association.
"The medicines now in the research pipeline will add to the substantial
progress made in the last five years by biopharmaceutical companies in
developing new and more effective neurological treatments," said PhRMA
President and CEO Billy Tauzin. "The growing number of older Americans
nationwide, who are susceptible to conditions such as Alzheimer's and
Parkinson's disease, will especially benefit from these new medicines. This
strong commitment to research is a product of the
'/>"/>
| SOURCE Pharmaceutical Research and Manufacturers of America Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Virginia Tech Report Has National Importance
2. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
3. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
4. Haemacure Reports Third Quarter 2007 Results
5. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
6. Biotech Finishes on a High in August, Burrill Report Says
7. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
8. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
9. MDS Reports Third Quarter 2007 Results
10. First New York/New Jersey Health Care Report Card Released
11. Authentidate Holding Corp. to Report Fourth Quarter and Fiscal 2007 Year End Results on Thursday, September 13, 2007
Post Your Comments:
(Date:12/4/2009)...ire/ -- Pamela Bowen, Chief Information Officer at...or the "Chief Innovation Officer" Appy Award for t...cloud computing. Appy Award recipients are nominat...RM or the Force.com platform in bringing new level...artner, service, support or IT organizations. ,...
(Date:12/4/2009)... cancers, particularly Ewing sarcomas and tumors o...tudy published online December 4 in the Journal o...as undertaken because there is limited research on...) for pediatric cancer patients. , Karen Wasilew...lood Disorders Service, Children,s Healthcare of A...
(Date:12/4/2009)... from the School of Medicine,s Department of Nutri...ch products of lipid peroxidation and some drugs o... The pathways were identified by a combination of ...dings shed new light on the mechanism of action of...wn as "the date rape drug." The manuscript publish...
(Date:12/4/2009)...phenomenon that was started by people that were lo...al work in the US, Canada, and other countries. In... have found that Mexican Dental Vacation is a grea... (PRWEB) December 4, 2009 -- Aft...n Dental Vacation is seeing their best year ever, ...
(Date:12/4/2009)...ators to crack down on abuse of opioid medications...The makers of 24 different prescription painkiller...s to curb the abuse of these opioid drugs. , T...re from U.S. Food and Drug Administration official...doses that occur with these medications each year,...
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2[0] Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist[0] News brief -- childhood cancer survivor study report: Late recurrence is a risk for some cancers[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor [0] Makers of Powerful Painkillers Present Safety Plans
..., yet 2 million people die of cardiovascular disea...e is now affecting younger generations due to unhe...ture deaths. Recent studies have highlighted the ... to develop national strategies to combat heart di...
...M) has,focused its culinary expertise this time to...u salivating for more. Italians have known for cen...age as natural as spaghetti and,meatballs. Now Twi...ew., (Photo: http://www.newscom.com/cgi-bin/prnh...
...lutions, Inc.,(Accuro) (http://www.accurohealth.c...cle management market with the acquisition of TPMS...rovides contract management services to a,strong c...MS,personnel to continue to provide the excellent ...
... Hyperion,Therapeutics, Inc., a privately held bio...S. Zoth has been elected to the company,s Board of...e President and Chief,Financial Officer of MedImmu...n discussing her appointment, Ms. Zoth commented, ...
...ncrease the bronchoscopy market, to approximately...earch Group, WALT...,Research Group,s US Markets for ENT & Bronchoscop... to $180 million by 2012., To date, the majority ...
...ific Corporation (NYSE: BSX ) today announced the...ounsel. Pratt is a nationally known,attorney speci...ation. He,will hold the title of "Executive Vice P...cer Jim Tobin. He plans to join,the Company May 1s...
Other Medicine News:Health News:Joining efforts to tackle heart disease 2Health News:Joining efforts to tackle heart disease 3Health News:New Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free Connoisseurs 2Health News:Hyperion Therapeutics Elects Lota Zoth to Board of Directors 2Health News:Interventional Pulmonology Creeping into Bronchoscopy Market 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 2Health News:Boston Scientific Announces Appointment of Timothy Pratt as General Counsel 3Joining efforts to tackle heart diseaseNew Twin Hens Beef Pot Pies with Organic Cornmeal Now Provide The Brand's Famous Artisan Comfort Food for Gluten-free ConnoisseursAccuro Healthcare Solutions Acquires TPMSHyperion Therapeutics Elects Lota Zoth to Board of DirectorsInterventional Pulmonology Creeping into Bronchoscopy MarketBoston Scientific Announces Appointment of Timothy Pratt as General Counsel
(Date:12/4/2009)..., , BILLERICA, Mass., Dec. 4 /PRNewswi...y-owned subsidiary of Volcano Corporation (Nasdaq:...and successful testing of a novel integrated light...ves this proprietary optical engine design raises ... limitations of laser-based designs for swept sour...
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 /PRNewswire-First...r the "Company") (OTC Bulletin Board: NWBO) announ...has allowed its patent application on a system for...re of the Company,s DCVax® therapeutic cancer... key to the very high concentration of dendritic c...
(Date:12/3/2009)..., , ALISO VIEJO, Calif. and STATE COLLEG...SoftGenetics today announced the signing of an agr... services using SoftGenetics, NextGENe software fo... Ambry. ,, (Logo: http://www.newscom.com/cg...sheidt PhD, Ambry,s CSO said, "Our team at Ambry h...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 1Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 2Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 3Frost 26amp 3B Sullivan Identifies Focus on Quality Management and Adoption of a Full service Model as Keys to the Growth of the European CRO Market 5373 4Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 1Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR 28TM 29 Technology and Generate Novel Drug Leads Against a GPCR 14426 3Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 1Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 2Plastic Surgeon in Orlando Florida Helping New Moms Enhance their Figures after Pregnancy with a Mommy Makeover 59276 3[0] Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging[0] Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing[0] Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
...s of Disease Activity as Measured,by MRI and Relap...ech, Inc.,(NYSE: DNA) and Biogen Idec, Inc. (Nasda... II clinical study of Rituxan®,(rituximab) in ...is,(RRMS) were presented today at the American Aca...ituxan is a therapeutic antibody,that targets and ...
... reduced by 40 percent compared,to delayed treatme...lthCare,Pharmaceuticals announced today new data, ...on(R) (interferon beta-1b) treatment in,patients w... (MS),can significantly reduce the risk of permane...nded Disability Status Scale,(EDSS) by 40 percent(...
Other Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 2First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 3First of Its Kind Data Show: Immediate Treatment of Early MS,Patients with Betaseron Significantly Delayed Permanent Disability 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |